Cristina Cassetti, Ph.D.

Similar documents
Application of Reverse Genetics to Influenza Vaccine Development

Pandemic Influenza influenza epidemic: realization of a worst-case scenario

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update

Lecture 19 Evolution and human health

Nanoparticulate Vaccine Design: The VesiVax System

Patricia Fitzgerald-Bocarsly

Modeling the Antigenic Evolution of Influenza Viruses from Sequences

Influenza Viruses A Review

IN VIVO STUDIES ON VIRAL VIRULENCE

TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?

Active and Passive Immunization for Avian Influenza Virus Infections

Influenza: Ecology and Continuing Evolution

Technology Overview. Summary

Introduction to Avian Influenza

Avian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

The H5N1 Influenza Controversy: Implications for Science Governance. Larry Kerr, PhD Senior Advisor to the Director for Global Biological Threats

Research Issues in Animal Surveillance and Pandemic Planning

Impact of Amino Acid Mutations in PB2, PB1-F2, and NS1 on the Replication and Pathogenicity of Pandemic (H1N1) 2009 Influenza Viruses

Evolution of influenza

Research with Dual Use Potential. Presentation Nancy Connell, Yousra Sobeih and Alastair Hay

Before and during influenza pandemics

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today

Where Health Care Meets Policy. with Dr. Mike Magee

Flu, Avian Flu and emerging aspects (H1N1 resistance)

Synthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)

Molecular Basis of Replication of Duck H5N1 Influenza Viruses in a Mammalian Mouse Model

Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment

The Origin and Virulence of the 1918 Spanish Influenza Virus 1

1/25/2013 1:56 PM. Hunting the 1918 Virus

Reverse genetic platform for inactivated and live-attenuated influenza vaccine

VIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks

Strategies for control of influenza by targeting broadly conserved viral features

Contribution of avian influenza data through OFFLU network

Influenza vaccines: present and future

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme

TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination

Importance of 1918 virus reconstruction on current assessments to pandemic risk

Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Preparing for the Fall Flu Season. Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP


Lecture 18 Evolution and human health

Current CEIRS Program

Unit 2: Lesson 2 Case Studies: Influenza and HIV LESSON QUESTIONS

Overview of the Influenza Virus

Biotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

The Controversy About the H5N1 Transmissibility Experiments. resumes on lethal flu strains

INFLUENZA-2 Avian Influenza

UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York

University of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009

Overview: Chapter 19 Viruses: A Borrowed Life

HS-LS4-4 Construct an explanation based on evidence for how natural selection leads to adaptation of populations.

C E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock

NIAID Oversight of Clinical Research and Funding Opportunities

Agricultural Outlook Forum Presented: February 16, 2006 THE CURRENT STATE OF SCIENCE ON AVIAN INFLUENZA

Human Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١

The Flu: The Virus, The Vaccine, and Surveillance. Joanna Malukiewicz GK12 Program School of Life Sciences Arizona State University

Chapter 19: The Genetics of Viruses and Bacteria

Biosafety and Bioethics

Vaccine. Design and Manufacturing. Liting Bi.

OFFLU Technical Meeting Coordinating world-wide surveillance for influenza in swine. OIE headquarters, Paris, France March 27-28, 2012

H5N1 avian influenza: timeline

Lecture 11. Immunology and disease: parasite antigenic diversity

What have we learned from H5N1?

The H5N1 case: A virologist s view

ph1n1 H3N2: A Novel Influenza Virus Reassortment

Influenza. By Allison Canestaro-Garcia. Disease Etiology:

numbe r Done by Corrected by Doctor

(the change introduced is to add a risk assessment, missing from the previous version, for small-scale laboratory work with characterized CVV)

Influenza: The past, the present, the (future) pandemic

Possible Modes of Transmission of Avian Viruses to People: Studies in Experimental Models

Advances in Viral Immunity Stemming from the 1918 Flu Pandemic

Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease

Housing of Different Infected Mice in the Same Room: How to Prevent Roommate Conflicts? Jocelyn Beaucher, PhD, microbiologist Biosafety Officer

Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso

Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine

Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them

Avian Influenza (Bird Flu) Fact Sheet

Current Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?

Emergence of distinct avian-like influenza A H1N1 viruses in pigs in Ireland and their reassortment with cocirculating H3N2 viruses

Influenza Genome Sequencing Project Proposal

OFFLU the joint OIE-FAO network of expertise on animal influenza

Alphabet Soup of Flu Strains

MINI-REVIEW. Protein & Cell. The emergence of pandemic influenza viruses

Relative activity (%) SC35M

RESEARCH WITH HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1

LESSON 4.5 WORKBOOK. How do viruses adapt Antigenic shift and drift and the flu pandemic

Segments 7 codes for M1 and M2 proteins (Matrix proteins)

PATH Influenza Vaccine Projects

INFLUENZA A VIRUS. Structure of the influenza A virus particle.

Influenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

Regulatory Challenges to Production of Veterinary Influenza Vaccines in Human Facilities

Pandemic Influenza: A Zoonotic Infection. Kathleen M. Neuzil, MD, MPH PATH University of Washington School of Medicine April 28, 2008

Phylogenetic Methods

Cover Page. The handle holds various files of this Leiden University dissertation

Studying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID

Product Development for Public Health & Emerging Infections

Avian Influenza Virus H7N9. Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences

Transcription:

NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID

Influenza virus

DMID Influenza Program Basic research (40 grants) Viral replication Structure and assembly Pathogenesis Virus-host interaction Viral Evolution Diagnostics (7 grants) Drug Discovery (3 grants) Vaccine development (10 grants)

Genetic rescue of influenza virus from cdnas From: Webby, R. and Webster R. Science 2003. 1519-1522

With the advent of reverse genetics Powerful tool to elucidate the biology of the virus: Custom-make recombinant influenza viruses containing specific genes. Introduce selected point mutations/deletions to evaluate the function of viral protein domains. Potentially faster and easier to generate of vaccine reference strains (used to make Vietnam H5N1 reference viruses). Eliminates the need for working directly with the clinical isolate. Can engineer HA of pandemic virus strains without the basic amino acids at the cleavage site (associated with high virulence).

Molecular basis for high virulence of 1997 H5N1 The H5N1 human isolates when tested in mice were divided into two groups: those strains that caused systemic lethal infection in the mice and those strains that were attenuated. Using reverse genetics the investigators systematically swapped the genes from the highly virulent viruses into the attenuated ones. The pathogenicity of these recombinant viruses was tested in mice. The PB2 gene was found to confer high lethality to the virus. Further testing revealed that a nucleotide change within the PB2 gene appeared to be key to the virus s virulence. The same mutation was observed in the H7N7 strain isolated from the lethal human case in the Netherlands and in the H5N1 virus isolated from lethal human cases in Vietnam in 2004. Hatta, M., Gao, P., Hoffmann, P., and Kawaoka, Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293(5536):1840-42 (2001).

H5N1 influenza virus gene suppresses the host immune responses The NS1 gene from a non-virulent viral strain was replaced with one from a 1997 H5N1 strain. Pigs infected with the recombinant virus experienced significant illness compared to the animals infected with the wild type strain. These results show that the H5N1 viruses that emerged in Hong Kong appear to have an NS1 gene that allows the virus to bypass the host defenses. These results provide an important target for ongoing surveillance efforts aimed at trying to identify the emergence of influenza strains with pandemic potential. Seo S, Hoffmann E, and Webster RG: Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nature Medicine 9:950 954, 2002.

NIAID seeks clues to the 1918 influenza pandemic Why was this strain so infectious and so lethal? Where did the virus come from? What are the genetic basis of its high virulence? In 1998 NIAID partially supported an expedition by an international team of scientist to obtain and study tissue samples from the bodies of 6 Norwegian miners who died of influenza in 1918 and were buried in the permafrost.

Sequencing of the1918 influenza virus Aim 1: complete sequencing of 1918 influenza genes. Completed: HA, NA, NS, NP and M genes. Nearly done: PB1, PB2 and PA. HA sequences from 6 different isolates from around the world have identified 1 mutation in HA. Aim 2: characterize pre- and post-1918 viruses to understand origin and evolution of this pandemic strain Data suggests that donor viruses for HA and NP genes was an avian influenza virus of unknown source. Crystal structure of 1918 HA protein, confirms that this protein had structural features primarily found in avian viruses. Stevens, J., Corper, A., Basler, C., Taubenberger, J., Palese, P., and Wilson, I: Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science, 303(5665):1866-70, 2004.

Characterization of recombinant influenza viruses containing five genes of the 1918 strain. Recombinant viruses containing the two major surface viral glycoproteins, HA and NA, of the 1918 strain are highly lethal in mice. Mice immunized with an inactivated influenza vaccine were completely protected from lethal challenge. This study provides important information on the pathogenicity of a pandemic virus and on the identification of vaccine strategies against emerging pandemic influenza strains. Tumpey, T., Garcia-Sastre, A., Taubenberger, J., Palese, P., Swayne, D., and Basler, C.: Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. PNAS 101(9):3166-71, 2004

Upcoming studies Further characterization of the 1918 strain Generation of new recombinant influenza viruses containing genes from highly pathogenic avian and human viral strains. Review of new grant applications = biohazard concerns + need guidance from NIH-OBA.

Current biosafety guidelines to work with influenza virus. Biosafety in Microbiological and Biomedical Laboratories, 4 th edition (May 1999). Agent: Influenza Activities Utilizing Non-contemporary virus strains: Research or production activities utilizing contemporary strains may be safely performed using Biosafety Level 2 containment practices. Susceptibility to infection with older noncontemporary human strains, with recombinants, or with animal isolates warrant use of Biosafety level 2 containment procedures.

NIAID Reverse Genetics Workshop, July 2001 Goal: Discuss several issues relating to biosafety of the natural and recombinant influenza viruses and the potential to generate 1918-like strains and recombinants. Outcome: Complex issue, rely on local IBCs, update BMBL. Future directions: another consensus meeting on the 1918 virus be held at a future time when more data would be available.

Summary and future directions BMBL currently being updated (Dr. Wilson, NIH Occupational Safety and Health Branch). More information available - NIAID seeking guidance from OBA and RAC committee on appropriate biocontainment level to be used when working with recombinant influenza viruses, especially those containing one or more genes from highly pathogenic avian and 1918 virus strains. Safety symposium being organized by OBA - Sept 2004